FIELD: medicine.
SUBSTANCE: invention relates to imaging agents used in non-invasive methods of fibrous disease diagnostics, fibrous disease control and method of determining effect of treating fibrotic diseases. Diagnostic technique for involves stage of visualizing agent containing retinoid and detected mark introduction in vivo, to test subject and control subject and step for comparing of signal intensity and/or distribution of mark signal detected in test subject, with change in 5-90 minutes after introduction, with change in 5-90 minutes after introduction of control signal intensity and/or distribution of reference signal mark detected in control subject.
EFFECT: methods of monitoring and determining effect of treating include stage of visualizing agent containing retinoid and detected mark administering in vivo, to subject and step of comparing signal intensity and/or distribution of mark signal, detected in first moment in time in individual with signal intensity and/or distribution of mark signal detected in said subject to second moment in time, which is later than first moment in time.
9 cl, 14 ex, 16 dwg
Title | Year | Author | Number |
---|---|---|---|
POLYGLUTAMATE-AMINO ACID CONJUGATES AND METHODS | 2006 |
|
RU2472812C2 |
CHELATE AMPHIPHILIC POLYMERS | 2009 |
|
RU2519713C2 |
DRUG CARRIERS | 2008 |
|
RU2505315C2 |
GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2821944C2 |
ANTIBODIES BINDING TO LYSYL OXIDASE-LIKE ENZYME-2 (LOXL2), AND METHOD FOR PREPARING THEM | 2011 |
|
RU2549684C2 |
NEW PSA-BINDING AGENTS AND THEIR USE | 2018 |
|
RU2787105C2 |
METHOD FOR IDENTIFYING SITES FOR IgG CONJUGATIONS | 2010 |
|
RU2569186C2 |
CONJUGATE INCLUDING LIGAND, SPACER, PEPTIDE LINKER AND BIOMOLECULE | 2020 |
|
RU2807081C2 |
ANTIBODIES SPECIFIC TO TUMOUR AND USE THEREOF | 2011 |
|
RU2595403C2 |
Authors
Dates
2016-09-10—Published
2009-09-11—Filed